An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.
Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 2021 Nov 2.
Science. 2021.
PMID: 34726479
Free article.